Mira provides an AI-powered fertility tracking device and platform for at-home hormone monitoring. The company's analyzer enables quantitative measurements of four key fertility hormones - E3G, LH, PdG, and FSH - through urine samples, eliminating the need for blood tests. Founded in 2018 and based in Pleasanton, California, the device is FDA and CE compliant, offering users detailed hormone pattern analysis through its mobile health platform. As of March 2024, Mira had sold over 130,000 devices through various retail outlets. The technology allows patients to monitor hormone levels from home while sharing results with healthcare providers through the accompanying app. This enables providers to gain deeper insights into hormone patterns throughout menstrual cycles and personalize treatment protocols.
Key customers and partnerships
In October 2019, Mira partnered with the Urgent Care Association to provide its members access to the company's nationwide network of urgent care centers. The partnership aimed to make healthcare more accessible and affordable for uninsured and underinsured Americans. Medical professionals, including reproductive endocrinologists and fertility specialists, have integrated Mira's technology into their practices to optimize treatment outcomes and reduce unnecessary clinic visits for patients.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.